Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents

Aims. to compare visual and anatomic outcomes of adjunct intravitreous (ivt) triamcinolone acetonide to antivascular endothelial growth factor (vegf) injections to ivt anti-vegf injections alone for center-involving diabetic macular edema (dme) in treatment-naïve eyes. methods. retrospective study of treatment-naïve eyes with center-involving dme. the primary outcome was the change in best corrected visual acuity (bcva) in eyes receiving only ivt anti-vegf (group 1) and eyes receiving ivt anti-vegf and adjunct ivt-ta (group 2). results. included were 192 eyes. the mean change in bcva was +3.5 letters in group 1 compared to-3.5 letters in group 2 (p=0.048). final macular thickness improved by-94 μm in group 1 versus-68 μm in group 2 (p=0.26). in group 1,5/150 eyes compared to 9/42 eyes in group 2 (3.3% versus 21%,p=0.0005) had a iop >10 mmhg increase. six of 126 phakic eyes in group 1 versus 12/33 phakic eyes in group 2 underwent cataract surgery (4.7% versus 36.3%,p=0.00009). conclusions. ivt-ta results in no additional benefit in eyes treated with anti-vegf agents for dme. © 2016 robert b. garoon et al.